SeaStar Medical Holding Corporation (ICU)
| Market Cap | 7.81M |
| Revenue (ttm) | 68,000 |
| Net Income (ttm) | -29.87M |
| Shares Out | 4.46M |
| EPS (ttm) | -10.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 163,174 |
| Open | 1.810 |
| Previous Close | 1.830 |
| Day's Range | 1.723 - 1.850 |
| 52-Week Range | 1.500 - 27.500 |
| Beta | -0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 15, 2025 |
About ICU
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquarter... [Read more]
Financial Performance
Financial StatementsNews
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market
DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced...
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial
DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing pr...
SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer
DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications
U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE...
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solut...
Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
The pace of patient enrollment has significantly accelerated following a summertime slowdown DENVER, Oct. 18, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-s...
SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week
DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
DENVER, Oct. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h...
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h...
SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Regulations And Stockholders Are Invited To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corp...
SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corpo...
ICU Deadline: Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of SeaStar Medical Hol...
SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corpo...